Evidence map›Paper›PMID 26714839›Full record

ArticleThe Prostate2016

Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation.

Ramakumar Tummala, Nagalakshmi Nadiminty, Wei Lou, Christopher P Evans, Allen C Gao

RetractedOpen access · greenAbstract readRetracted Publication
In one paragraph

Article in The Prostate, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. LIN28B promotes the development of neuroendocrine prostate cancer.The Journal of clinical investigation · 2020
    Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. The LIN28/let-7 Pathway in Cancer.Frontiers in genetics · 2017
    Review
  14. Article
  15. Cancer genomics & proteomics
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ramakumar TummalaDepartment of Urology, University of California at Davis, Sacramento, California.
Nagalakshmi NadimintyDepartment of Urology, University of California at Davis, Sacramento, California.
Wei LouDepartment of Urology, University of California at Davis, Sacramento, California.
Christopher P EvansDepartment of Urology, University of California at Davis, Sacramento, California.
Allen C GaoDepartment of Urology, University of California at Davis, Sacramento, California.
University of California, Davis · US

Funding

Novel roles of microRNA in androgen receptor signalingR01CA168601 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI GAO, ALLEN C. · 2013 to 2017
$1.5M
Interleukin-6 and castration-resistant prostate cancerR01CA140468 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI GAO, ALLEN C. · 2010 to 2014
$1.5M
(PQD-1) NF-kB activation and enzalutamide therapy in metastatic castration resistR21CA179970 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI GAO, ALLEN C. · 2013 to 2014
$363k
Role of Rho GDP dissociation inhibitors in androgen signaling in prostate cancerI01BX000526 · VA · VA NORTHERN CALIFORNIA HEALTH CARE SYS · PI GAO, ALLEN C. · 2011 to 2013
–
The role of p52 in prostate cancerI01BX002653 · VA · VA NORTHERN CALIFORNIA HEALTH CARE SYS · PI GAO, ALLEN C. · 2014 to 2017
–
BLRD VA I01 BX000526BLRD VA I01 BX002653NCI NIH HHS CA140468NCI NIH HHS CA168601NCI NIH HHS CA179970NCI NIH HHS R01 CA140468NCI NIH HHS R01 CA168601NCI NIH HHS R21 CA179970
6 · The paper itself

Abstract

backgroundProstate cancer (PCa) is androgen-dependent initially and progresses to a castration-resistant state after androgen deprivation therapy. Treatment options for castration-resistant PCa include the potent second-generation anti-androgen enzalutamide or CYP17A1 inhibitor abiraterone. Recent clinical observations point to the development of resistance to these therapies which may be mediated by constitutively active alternative splice variants of the androgen receptor (AR).

methodsSensitivity of LNCaP cells overexpressing Lin28 (LN-Lin28) to enzalutamide, abiraterone, or bicalutamide was compared to that of control LN-neo cells using cell growth assays, proliferation assays using MTT, anchorage-dependent clonogenic ability assays and soft agar assays. Ability of LN-Lin28 cells to maintain AR activation after treatment with enzalutamide, abiraterone, or bicalutamide was tested using immunofluorescence, Western blotting, ChIP assays, and qRT-PCR. Importance of Lin28 in enzalutamide resistance was assessed by the downregulation of Lin28 expression in C4-2B and 22Rv1 cells chronically treated with enzalutamide. Requirement for sustained AR signaling in LN-Lin28 cells was examined by the downregulation of either full length AR or AR-V7 using siRNA.

resultsWe show that Lin28 promotes the development of resistance to currently used targeted therapeutics by enhancing the expression of AR splice variants such as AR-V7. PCa cells overexpressing Lin28 exhibit resistance to treatment with enzalutamide, abiraterone, or bicalutamide. Downregulation of Lin28 resensitizes enzalutamide-resistant PCa cells to enzalutamide treatment. We also show that the upregulation of splicing factors such as hnRNPA1 by Lin28 may mediate the enhanced generation of AR splice variants in Lin28-expressing cells.

conclusionsOur findings suggest that Lin28 plays a key role in the acquisition of resistance to AR-targeted therapies by PCa cells and establish the importance of Lin28 in PCa progression.

Indexed as

Alternative SplicingAndrogen AntagonistsCell Line, TumorDisease ProgressionDrug Resistance, NeoplasmHumansMaleProstatic Neoplasms, Castration-ResistantProtein IsoformsReceptors, AndrogenRNA-Binding ProteinsAndrogen AntagonistsLin28A protein, humanProtein IsoformsReceptors, AndrogenRNA-Binding Proteinsanti-androgensAR variantsLin28resistance

Identifiers

PMID26714839
PMCPMC5372699
OpenAlexW2205047772

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.